Mylan’s Plan to Copycat Botox Creates a Familiar Wrinkle for Allergan

Allergan Plc faces another risk after the generic drugmaker Mylan NV announced plans to align itself with a small-cap competitor and develop a biosimilar to Allergan’s top-selling wrinkle treatment and therapeutic agent, Botox.

While threats to Allergan’s Botox franchise are nothing new, just how real this one may be is still up for debate.